Sol-Gel Technologies Ltd.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Sol-Gel Technologies
Pharmaceutical Preparations, SIC 2834
Sol-Gel Technologies Ltd. is a clinical-stage dermatology company focused on identifying, developing, and commercializing topical therapies for skin conditions. Its commercial portfolio includes Twyneo, an FDA-approved non-antibiotic topical cream for acne vulgaris, and Epsolay, an approved encapsulated benzoyl peroxide cream for papulopustular rosacea. In addition to commercialized treatments, the company is advancing an investigational pipeline that includes SGT-610 (patidegib gel) for preventing basal cell carcinomas in Gorlin syndrome patients and SGT-210 (erlotinib) for localized epidermal growth factor receptor inhibition. Its target customer base consists of patients requiring specialized dermatological medical treatments.
The company maintains its principal executive offices in Ness Ziona, Israel. Commercial distribution and product development are conducted internationally, with active commercialization, licensing, and purchase agreements supporting operations across target territories including the United States, Canada, and China. Research, development, and administrative activities are supported by internal operations and contracted third-party manufacturing organizations.
Summary of the business section of Sol-Gel Technologies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Sol-Gel Technologies Ltd.
- Founded
- 1997
- Headquarters
- Ness Ziona, Israel
- Address
- 7 Golda Meir St., Weizmann Science Park 7403648
- Phone
- 97289313433
- Website
- sol-gel.com
- Employees
- 28, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- Kesselman & Kesselman, Tel-Aviv, Israel
Stock & identifiers
- Ticker
- SLGL
- Exchange
- Nasdaq
- IPO date
- Feb 2, 2018
- Shares outstanding
- 3M, Dec 31, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-10 reverse, Aug 15, 2025; 1-for-10 reverse, May 5, 2025
- SEC CIK
- 1684693
- CUSIP
- M8694L137
- ISIN
- USM8694L1375
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Moshe Arkin | Chairman of Board and CEO, Director | 1,750,113 |
| Ofer Toledano | VP Research & Dev. | 1,461 |
| Itzik Yosef | Chief Operating Officer | – |
| Eyal Ben-Or | Chief Financial Officer | 1,000 |
| Ofra Levy-Hacham | VP Clinical, Reg & Quality | – |
| Michael Glezin | Chief Business Officer | 1,500 |
| Itai Gidon Arkin | Director | – |
| Ran Gottfried | Director | 1,550 |
| Sharon Kochan | Director | – |
| Yuval Yanai | Director | – |
| Hanna Lerman | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 28 employees, all of whom are located”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 2, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 26, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |